With the explosive excitement and clinical proof of concept utilizing CD47 approaches, 2020 is the year for macrophage development, as we witness greater interest and investment in new work on novel macrophage targets outside of CD47. 

Tumor Myeloid Microenvironment Directed Therapeutics Summit is focused on optimizing the potential of immunotherapy, through direct modulation of tumor-resident myeloid populations to retune the microenvironment for improved response rates to therapy. Additionally, we’ll take close look at how therapeutics can be designed to directly stimulate these populations to kill cancer 

Join us online in March as the trailblazers of myeloid directed therapeutic development, from the likes ofCarisma Therapeutics, Pfizer, Merck & Co., andVerseau Therapeutics come together to advance the fundamental understanding of macrophage biology, avoiding on-target toxicities and the emerging field of macrophage cellular immunotherapy. 

Here is a snapshot of the top 5 discussion you can’t afford to miss: